文献速递前列腺癌

经会阴前列腺穿刺活检提高主动监测中临床显著前列腺癌检出率

Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance.
PubMed 文献 · J Urol · 2020-12-01

该研究基于主动监测登记数据库,比较经会阴与经直肠前列腺穿刺活检在极低危或低危前列腺癌患者中的升级检出率。结果显示经会阴组升级至GG≥2的比例为21.2%,显著高于经直肠组的14.7%(p=0.01),且前部/移行区检出比例更高。校正混杂因素后,经会阴活检与GG≥2升级显著相关(OR 1.49,95%CI 1.11-2.19,p=0.01)。

要点

  • 经会阴穿刺活检使GG≥2升级检出率提高至21.2%,经直肠为14.7%。
  • 经会阴组前部/移行区GG≥2检出占比44%,高于经直肠组的18.7%。
  • 校正后经会阴活检与GG≥2升级独立相关(OR 1.49,95%CI 1.11-2.19)。

核心结论

  • 在极低危或低危前列腺癌主动监测患者中,经会阴前列腺穿刺活检与升级为临床显著前列腺癌的可能性增加相关。
  • 该关联可能源于经会阴途径对前列腺前部采样更充分。

研究设计与样本

  • 回顾性队列研究,查询本机构主动监测登记数据库。
  • 纳入2017年11月至2020年6月间接受监测活检的790例极低危或低危前列腺癌患者。
  • 按活检方式分为经会阴组(279例)和经直肠组(511例),比较基线特征和癌症升级率。

主要发现

  • 经会阴组59/279(21.2%)升级至GG≥2,经直肠组75/511(14.7%),p=0.01。
  • 升级至GG≥2的患者中,经会阴组26/59(44%)在前部/移行区检出GG≥2,经直肠组14/75(18.7%),p=0.01。
  • 经会阴组17/279(6.1%)升级至GG≥3,经直肠组17/511(3.3%),p=0.05。
  • 校正年龄、PSA密度、MRI使用和既往经直肠活检次数后,经会阴活检与GG≥2升级显著相关(OR 1.49,95%CI 1.11-2.19,p=0.01)。

临床怎么用

  • 对主动监测中的极低危或低危前列腺癌患者,经会阴穿刺可能更准确地检出前部/移行区的临床显著癌。
  • 临床决策时应考虑活检途径对升级检出率的影响,避免因经直肠活检漏检前部病灶而低估风险。

局限性

  • 本研究为单中心回顾性登记分析,可能存在选择偏倚。
  • 样本来自特定机构且时间跨度有限,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Transperineal prostate biopsy offers improved sampling of the anterior prostate compared to the transrectal approach. The objective of this study was to determine if transperineal prostate biopsy is associated with an increased incidence of cancer upgrading among men on active surveillance for very low or low risk prostate cancer. MATERIALS AND METHODS: Our active surveillance registry was queried to identify patients who underwent a surveillance biopsy following the introduction of transperineal prostate biopsy at our institution. Patients were dichotomized by the type of biopsy performed. The baseline characteristics and rates of cancer upgrading were compared between groups. RESULTS: Between November 2017 and June 2020, 790 men with very low or low risk prostate cancer underwent a surveillance biopsy. In total, 59 of 279 men (21.2%) in the transperineal prostate biopsy group were upgraded to grade group ≥2 as compared to 75 of 511 (14.7%) in the transrectal biopsy group (p=0.01). Among patients who were upgraded to grade group ≥2, 26 of 59 (44%) had grade group ≥2 detected in the anterior/transition zone with transperineal prostate biopsy compared to 14 of 75 (18.7%) with transrectal biopsy (p=0.01). Additionally, 17 of 279 men (6.1%) who underwent transperineal prostate biopsy were upgraded to grade group ≥3 vs 17 of 511 (3.3%) who underwent transrectal biopsy (p=0.05). After adjusting for age, prostate specific antigen density, use of magnetic resonance imaging, and number of prior transrectal biopsies, transperineal prostate biopsy was significantly associated with upgrading to grade group ≥2 (OR 1.49, 95% CI 1.11-2.19, p=0.01). CONCLUSIONS: Among men on active surveillance for very low or low risk prostate cancer, transperineal prostate biopsy was associated with an increased likelihood of upgrading to clinically significant prostate cancer. This is likely due to improved sampling of the anterior prostate with the transperineal approach.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Meyer AR, Mamawala M, Winoker JS, et al. Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. J Urol. 2020. PMID: 33487007. doi:10.1097/JU.0000000000001523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。